Patent Application
20110274680
The present invention relates to synergistic chemical compositions of bioactive compounds in a dietary supplement for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases. The present invention relates to chemical compositions of a sugar free sweetener/super sweetener for people with Type-2 Diabetes disease. The present invention also relates to a nano encapsulation and targeted nano delivery of bioactive compounds and/or bioactive molecules for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases. Furthermore, the present invention also relates to microelectro-mechanical system (MEMS) based passive and active delivery of bioactive compounds and/or bioactive molecules.
One of the most intriguing discoveries is that many risk factors for Cardiovascular, Type-1 Diabetes and Type-2 Diabetes diseases are risk factors for Alzheimer's disease (also known as Type-3 Diabetes disease).
Studies suggest that high blood cholesterol levels are important risk factors for Alzheimer's disease. If blood flow is restricted because of a buildup of plaque in brain cells, less oxygen gets to the brain and fewer waste residues leave the brain.
Type-1 Diabetes disease is caused by autoimmune destruction of insulin-producing cells in the pancreas, resulting in high blood sugar. The drugs that block Effector Memory T cells, may offer some hope of delaying Type-1 Diabetes disease.
Type-2 Diabetes disease is linked to metabolic syndrome/obesity—hence macrophages in fat tissues. The macrophages in fat tissues produce “cytokine” molecules, which cause inflammations in the pancreas. Such inflammations in the pancreas increase the insulin (a hormone needed to convert carbohydrates, glucose and others foods into energy needed for daily life) resistance. Gradually the pancreas loses its ability to produce insulin.
Diabetes disease is marked by high levels of blood glucose resulting from defects in insulin production and/or inaction. Diabetes disease can lead to serious complications (e.g., kidney disease, high blood pressure, stroke and premature death). But people with Diabetes disease can control/manage the disease and lower the risks of serious complications.
The present invention relates to synergistic chemical compositions of bioactive compounds in a dietary supplement for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases.
Furthermore, the present invention relates to chemical compositions of a sugar free super sweetener for people with Type-2 Diabetes disease.
Furthermore, the present invention relates to a nano encapsulation and targeted nano delivery of bioactive compounds and/or bioactive molecules for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases.
Furthermore, the present invention relates to a microelectro-mechanical system (MEMS) enabled passive delivery of bioactive compounds and/or bioactive molecules.
Furthermore, the present invention relates to a MEMS enabled active (based on feedback diagnostics data) delivery of bioactive compounds and/or bioactive molecules.
The present invention is better understood upon consideration of the description in conjunction with the following tables and drawings.
Table-1 illustrates a synergistic chemical (solid) composition of a dietary supplement for lowering the risks of Alzheimer's disease.
Table-2 illustrates a synergistic chemical (solid) composition of a dietary supplement for lowering the risks of Cardiovascular disease.
Table-3 illustrates a synergistic chemical (solid) composition of a dietary supplement for lowering the risks of Type-2 Diabetes disease.
Table-4 illustrates a synergistic chemical (liquid) composition of a super antioxidant dietary supplement/tonic for lowering the risks of Alzheimer's, Cardiovascular and Type-2 Diabetes diseases.
Table-5 illustrates a synergistic chemical (solid) composition of a sugar free sweetener for people with Type-2 Diabetes disease.
Table-6, Table-7, Table-8, Table-9, Table-10, Table-11, Table-12 Table-13, Table-14, Table-15, Table-16, Table-17 and Table-18 illustrate a synergistic chemical (solid) composition of a sugar free super sweetener for people with Type-2 Diabetes disease.
[Bioactive Compounds &/or Bioactive Molecules Interactions with Genes/Proteins]
Furthermore, from the analysis of the above, it was found that Alzheimer's disease related gene/protein APOE is also linked with Type-2 Diabetes disease related gene/protein HNF4A.
Bacopa monnieri
+
Camellia sinensis
+ (Black)
Camellia sinensis
+ (Green)
Camellia sinensis
+ (White)
Cinnamomum zeylanicum
+
Curcuma longa
+ (Or Curcumin
Evolvulus alsinoide
+
Hypericum perforatum
+
Mucuna pruriens
+
Nigella sativa/kalonji+
Paeoniae alba
+
Salvia miltiorrhiza
+
Withania somnifera
+
Crataegus oxyacantha
+
Inula racemosa
+
Irvingia gabonensis
+
Terminalia arjuna
+
Andrographis paniculata
+
Artemisia princeps
+
Camellia sinensis
+ (Black)
Camellia sinensis
+ (Green)
Camellia sinensis
+ (White)
Cinnamomum zeylanicum
+
Coccinia indica
+
Euterpe oleracea
+
Hippophae rhamnoides
+
Irvingia gabonensis
+
Lycium barbarum
+
Momordica charantia
+
Nigella sativa/kalonji+
Phyllanthus emblica
+
Punica granatum
+
Salacia oblonga
+
Vitis spp.+
Aronia melanocarpa
+, Citrus
limonum
+, Daucus carota+,
Hibiscus spp.+, Malus domestica+,
Ribes nigrum
+, Sambucus nigra+
Actinidia chinenesis
+
Ananas comosus
+
Cocos nucifera
+
Garcinia mangostana
+
Litchi chinensis
+
Vitis spp.+
Aronia melanocarpa
+, Citrus limonum+, Daucus carota+,
Hibiscus spp.+, Malus domestica+, Ribes nigrum+,
Sambucus nigra
+ and Vaccinium spp. + - each is about
Stevia rebaudiana
+
Capparis masaikai
+ (Mabinlins Protein)
Stevia rebaudiana
+
Curculigo latifolia
+ (Curculin Protein)
Stevia rebaudiana
+
Dioscoreophyllum cumminsii
+ (Monellin Protein)
Stevia rebaudiana
+
Momordica grosvenorii/Siraitia grosvenorii+
Stevia rebaudiana
+
Pentadiplandra brazzeana
+ (Brazzein Protein)
Pentadiplandra brazzeana
+ (Pentadin Protein)
Stevia rebaudiana
+
Stevia rebaudiana
+
Synsepalum dulcificum
+ (Miraculin Protein)
Stevia rebaudiana
+
Thaumatococcus daniellii
+ (Thaumatin Protein)
Dioscoreophyllum cumminsii
+ (Monellin Protein)
Pentadiplandra brazzeana
+ (Brazzein Protein)
Pentadiplandra brazzeana
+ (Pentadin Protein)
Stevia rebaudiana
+
Dioscoreophyllum cumminsii
+ (Monellin Protein)
Pentadiplandra brazzeana
+ (Brazzein Protein)
Pentadiplandra brazzeana
+ (Pentadin Protein)
Synsepalum dulcificum
+ (Miraculin Protein)
Stevia rebaudiana
+
Capparis masaikai
+ (Mabinlins Protein)
Dioscoreophyllum cumminsii
+ (Monellin Protein)
Pentadiplandra brazzeana
+ (Brazzein Protein)
Pentadiplandra brazzeana
+ (Pentadin Protein)
Synsepalum dulcificum
+ (Miraculin Protein)
Stevia rebaudiana
+
Curculigo latifolia
+ (Curculin Protein)
Dioscoreophyllum cumminsii
+ (Monellin Protein)
Pentadiplandra brazzeana
+ (Brazzein Protein)
Pentadiplandra brazzeana
+ (Pentadin Protein)
Synsepalum dulcificum
+ (Miraculin Protein)
Stevia rebaudiana
+
Capparis masaikai
+ (Mabinlins Protein)
Curculigo latifolia
+ (Curculin Protein)
Dioscoreophyllum cumminsii
+ (Monellin Protein)
Pentadiplandra brazzeana
+ (Brazzein Protein)
Pentadiplandra brazzeana
+ (Pentadin Protein)
Synsepalum dulcificum
+ (Miraculin Protein)
Stevia rebaudiana
+
Capparis masaikai
+ (Mabinlins Protein)
Curculigo latifolia
+ (Curculin Protein)
Dioscoreophyllum cumminsii
+ (Monellin Protein)
Pentadiplandra brazzeana
+ (Brazzein Protein)
Pentadiplandra brazzeana
+ (Pentadin Protein)
Synsepalum dulcificum
+ (Miraculin Protein)
Stevia rebaudiana
+
+means extract from any part of the plant
Bioactive compounds and/or bioactive molecules usually get destroyed by acids/enzymes in the digestive system and only a tiny fraction of the bioactive compounds and/or bioactive molecules are absorbed in the blood stream.
Hydroxyapatite is a form of calcium phosphate with a chemical formula Ca10(PO4)6(OH)2.
Synthasome is a spherical hollow nanoshell. It contains an aqueous solution for protecting the bioactive compound 100 and/or bioactive molecule 100A. The synthasome has nano sized channels (e.g., a transmembrane protein) to permit or deny transport of a substance across the synthasome membrane. Furthermore, use of any synthetic polymer material to manufacture synthasome can enable to customize the characteristics (e.g., control permeability, release rate and stability) of the synthasome membrane.
Other nanoshells are dendrimer, ethosome, glycosome, noisome and polymeric micelle.
The interior surface of the nanoshell 120 can be electrically charged (e.g., the interior surface of the nanoshell can have an opposite electrical charge polarity with respect to the electrical charge polarity of the bioactive compound 100 and/or the bioactive molecule 100A encapsulated/caged in the nanoshell 120) to increase the encapsulation efficiency of the bioactive compound 100 and/or bioactive molecule 100A.
The exterior surface of the nanoshell 120 can also be electrically charged to increase the delivery efficiency of the bioactive compound 100 and/or bioactive molecule 100A.
Optionally a fluorophore (preferably a quantum dot/3-D photonic crystal) (e.g., 120B as in
To construct a capsosome, a polymer film is deposited onto small silica spheres. This polymer film is modified with cholesterol. Liposomes (coated with a functional surface (e.g., polyethylene glycol molecule) to shield from the body's immune surveillance and a targeting ligand to deliver encapsulated/caged with the bioactive compound 100 and/or bioactive molecule 100A at specific cells) are anchored to the cholesterol. Subsequently, more polymer films are added and cross-linked by disulfide bridges. Finally, the small silica spheres are finally etched away.
The functional surface 140 protects both the nanoshell 120 and the nanocarrier 160 from acids/enzymes in the digestive system.
Another functional surface (e.g., polyethylene glycol molecule) 180 on the nanocarrier 160 shields the nanocarrier 160 from the body's inherent immune surveillance.
Optionally a fluorophore (preferably a quantum dot/3-D photonic crystal) (e.g., 120B as in
A targeting ligand-cobalamin/vitamin B12 200 (on functional surface 180 of the nanocarrier 160) recognizes and attaches/locks onto the specific types of biological receptors 240A on the intestinal cells 260 (of the small intestinal walls 280).
Another targeting ligand-antibody 220 (on functional surface 180 of the nanocarrier 160) recognizes and attaches/locks onto the specific types of biological receptors 240B on the intestinal cells 260.
Both targeting ligands—(a) cobalamin/vitamin B12 200 and (b) an antibody 220 (on the functional surface 180 of the nanocarrier 160) act as dual navigators, guiding the nanocarrier 160 to the intestinal cells 260.
The nanocarrier 160 reaches and sticks to the intestinal cells 260, having the biological receptors 240, specifically 240A and 240B on the intestinal cells 260.
Both the nanocarrier 160 and the nanoshell 120, eventually breaks under an external condition (e.g., pH), allowing the bioactive compound 100 and/or bioactive molecule 100A to leak out from the nanoshell 120 into the intestinal cells 260, so that the bioactive compound 100 and/or bioactive molecule 100A can be absorbed in a controlled manner for a longer period of time in the blood stream.
Optionally, the nanoshell 120, (integrated with the functional surface 140, the functional surface (e.g., polyethylene glycol molecule) 180 to shield from the body's inherent immune surveillance, an optional fluorophore and the targeting ligands—(a) cobalamin/vitamin B12 200 and (b) the antibody 220) can be directly utilized instead of the nanocarrier 160. The nanoshell 120, eventually breaks under an external condition (e.g., pH), allowing the bioactive compound 100 and/or the bioactive molecule 100A to leak out from the nanoshell 120 into the intestinal cells 260, so that the bioactive compound 100 and/or bioactive molecule 100A can be absorbed in a controlled manner for a longer period of time in the blood stream.
This charge conjugation is optional, but it increases both the encapsulation and delivery efficiency of the bioactive compounds 100 and/or bioactive molecules 100A.
For example, the above nano assembly 4F with curcumin and curcumin-derived synthetic molecules (FLLL-11, FLLL-12, GO-Y030 and GO-Y031) can be an effective therapy against cancer (including brain cancer).
For example, the above nano assembly 4F with acetyl-L-carnitine, curcumin, curcumin-derived synthetic molecules (FLLL-11, FLLL-12, GO-Y030 and GO-Y031), L-DOPA and melatonin can cross blood brain barrier and can be an effective therapy against neurodegenerative diseases (e.g., Alzheimer's and/or Parkinson's diseases).
For example, the above nano assembly 4F with luric acid can be an effective therapy against acne.
For example, the above nano assembly 4F with nitrous oxide can be an effective therapy against erectile dysfunction.
For example, the above nano assembly 4F with micro-RNA (mi-RNA) or small interfering RNA (si-RNA) can be an effective therapy against various diseases.
The above nano assembly 4I can be utilized for controlled delivery of the bioactive compounds 100 and/or bioactive molecules 100A over a longer period of time.
The top surface of the MEMS reservoir 300 is 300B.
The bottom surface of the MEMS reservoir 300 is 300A. 300A is semi-porous for sustainable and/or controlled delivery of the bioactive compounds 100 and/or bioactive molecules 100A.
The bottom semi-porous surface of the MEMS reservoir 300 is 300A. 300A is attached onto a transport medium (e.g., a tissue/skin).
Applications of the above 4M are delivery of any drug (e.g., acetyl-L-carnitine, antibiotics, insulin, L-DOPA, luric acid, melatonin and nitrous oxide).
The semi-porous adhesive thin-film 320B is attached onto the transport medium.
Such a passive delivery of the bioactive compounds 100 and/or bioactive molecules 100A is typically limited by a low permeability of the bioactive compounds 100 and/or bioactive molecules 100A in the transport medium.
The microneedles 340 are about 450 micron long with an internal hole-diameter of about 45 micron.
The MEMS reservoir 300 is connected to a microflow tube 360, which is further connected to a micropump 380; the micropump 380 is powered by an electrical power component 400.
Such a MEMS biomodule configuration 420 is utilized to achieve a higher permeability through the transport medium for delivering bioactive compounds 100 and/or bioactive molecules 100A.
Incident light from the laser 580 is split through the optical beam splitter 560 (the incident light is measured by the spectrophotometer 600 as a reference), then absorbed by the fluorophore 120B, attached to a disease specific biomarker 460, on the receptor 240C, on the biomolecular interface layer 480, on the 2-D photonic crystal cavity 500 and then the emitted fluorescence wavelength from the fluorophore(s) 120B attached to a disease specific biomarker 460, on the receptor 240C, on the biomolecular interface layer 480, on the 2-D photonic crystal cavity 500 is measured by the spectrophotometer 600.
The Stokes Shift is the difference between the absorption wavelength and fluorescence emission wavelength by the fluorophore 120B. The Stokes Shift can be utilized to detect a presence of a specific disease.
There is a predictable correlation between the physical diameter (e.g., from 5 nm to 10 nm) of a quantum dot/3-D photonic crystal fluorophore 120B and the fluorescence emission wavelength by the fluorophore 120B. This predictable correlation can be utilized to detect the simultaneous multi-color fluorescence from many biomarkers related to a specific disease (e.g., Alzheimer's) and/or multiple diseases (e.g., Alzheimer's and Cardiovascular).
Furthermore, the above MEMS module can consists of an array of: micro needles 340, micromachined membranes 660, membrane sensors 680 and microfludic channels 620.
To enable a detachable/removable MEMS module to draw the patient's blood; an array of microfluidic channels 620, placed on an array of precise silicon/ceramic v-groves 640, within a precisely machined connector, can be utilized.
The micropump 380 can be continuously programmed (electronically and/or wirelessly) in a closed feedback loop to deliver the bioactive compounds 100 and/or bioactive molecules 100A based on the Stokes Shift.
Alternatively, the micropump 380 can be continuously programmed (electronically and/or wirelessly) in a closed feedback loop to deliver the bioactive compounds 100 and/or bioactive molecules 100A based on change in electrical characteristics of a graphene field effect transistor (FET) due to a disease specific biomarker 460, on the receptor 240C, on the biomolecular interface layer 480, on the single layer graphene 820.
Furthermore, the above MEMS module can consists of an array of: micro needles 340, micromachined membranes 660, membrane sensors 680 and microfludic channels 620.
To enable a detachable/removable MEMS module to draw the patient's blood, an array of microfluidic channels 620, placed on an array of precise silicon/ceramic v-groves 640, within a precisely machined connector, can be utilized.
The electronic module 940 includes at least an electrical power component 400, a microprocessor component 860, a memory/data storage component 880, a low-power wireless communication component 900 and an embedded operating algorithm 920, which can further interact with an intelligent expert diagnostic algorithm of diseases at a remote/cloud server.
Furthermore, the micro patch component 1140 can include a MEMS reservoir to store 120Fs.
The radio component 1020 is utilized for communicating (wirelessly) a disease condition analyzed by the biosensor read-out component 1060 (when a disease is detected by the biosensor component 1080).
An array of multi-wavelength (blue, green and red) quantum dot displays can be constructed as follows: optically pumps different-sized photonic crystals, whereas the photonic crystals can individually emit blue, green and red light based on their inherent sizes.
An optical pump can be generated from an optical emission by an electrical activation of semiconductor quantum-wells. Blue, green and red light can be multiplexed/combined to generate an array of quantum dot displays. The semiconductor quantum-wells are sandwiched between indium tin oxide (ITO) transparent front electrode and metal (e.g., aluminum or silver) back electrode.
An array of quantum dot displays can be manufactured by a contact printing process on a rigid (e.g., glass) or a flexible (e.g., plastic/graphene) substrate.
The solar cell component can be either a semiconductor (e.g., silicon) or a dye-sensitized based. A dye-sensitized solar cell consists of about two (2) micron thick meso-porous titanium oxide semi-conductor thin-film. This titanium oxide thin-film is coated with many types of light-absorbing organic dye molecules (e.g., porphyrins and phthalocyanines) embedded in nano crystals (e.g., 120A in
Furthermore, the electrodes are deposited/printed and etched on glass and/or plastic substrate. Sunlight, through indium tin oxide transparent front electrode striking many light-absorbing organic dye molecules, frees negative charged electrons and creates positive charged “holes”, where the electrons are lost. The semi-conducting titanium dioxide particles collect the electrons and transfer them to an external circuit, producing an electric current.
Definition: Component means any one of the following: a bioactive compound, a bioactive molecule, a functional molecule, a fluorophore, an electrical charge, an electronic component, an optical component and an algorithm.
[A] A neuro-protective dietary supplement includes: a) components of: Bacopa monnieri, Camellia sinensis, Cinnamomum zeylanicum, Curcuma longa, Evolvulus alsinoide, Mucuna pruriens and Withania somnifera.
Furthermore, the above neuro-protective dietary supplement includes: one or more components of: Hypericum perforatum, Nigella sativa/kalonji, Paeoniae alba and Salvia miltiorrhiza.
Furthermore, the above neuro-protective dietary supplement includes: one or more components of: Aronia melanocarpa, Citrus limonum, Daucus carota, Hibiscus spp., Malus domestica, Ribes nigrum, Sambucus nigra and Vaccinium spp.
Furthermore, the above neuro-protective dietary supplement includes: one or more components of: caffeine, citicoline, creatine and D-Ribose.
Furthermore, the above neuro-protective dietary supplement includes: one or more components of: acetyl-L-carnitine, coenzyme Q10, lipoic acid, melatonin, theanine and uric acid.
Furthermore, the above neuro-protective dietary supplement includes: one or more curcumin-derived synthetic molecules of: FLLL-11, FLLL-12, GO-Y030 and GO-Y031.
Furthermore, the above neuro-protective dietary supplement includes: one or more components of: ebselen (or glutathione or N-acetyl-L-cysteine) and nano encapsulated superoxide dismutase (SOD).
Furthermore, the above neuro-protective dietary supplement includes: one or more components of: pterostilbene, quercetin and resveratrol.
Furthermore, the above neuro-protective dietary supplement includes: one or more components of: a mineral and a vitamin.
[B] A cardiovascular disease risk reducing dietary supplement includes: Crataegus oxyacantha, Inula racemosa, Irvingia gabonensis and Terminalia arjuna.
Furthermore, the above cardiovascular disease risk reducing dietary supplement includes: one or more components of: Aronia melanocarpa, Citrus limonum, Daucus carota, Hibiscus spp., Malus domestica, Ribes nigrum, Sambucus nigra and Vaccinium spp.
Furthermore, the above cardiovascular disease risk reducing dietary supplement includes: one or more components of: ebselen (or glutathione or N-acetyl-L-cysteine) and nano encapsulated superoxide dismutase (SOD).
Furthermore, the above cardiovascular disease risk reducing dietary supplement includes: one or more components of: plant sterol, pterostilbene, quercetin and resveratrol.
Furthermore, the above cardiovascular disease risk reducing dietary supplement includes: one or more components of a mineral and a vitamin.
[C] A Type-2 Diabetes disease risk reducing dietary supplement includes: a) Touchi extract b) components of: Coccinia indica, Irvingia gabonensis, Momordica charantia and Salacia oblonga and c) acetyl-L-carnitine, beta glucan, coenzyme Q10, lipoic acid and nobiletin (or naringenin).
Furthermore, the above Type-2 Diabetes disease risk reducing dietary supplement includes: one or more components of: Andrographis paniculata, Artemisia princeps and Nigella sativa/kalonji.
Furthermore, the above Type-2 Diabetes disease risk reducing dietary supplement includes: one or more components of: Camellia sinensis, Euterpe oleracea, Hippophae rhamnoides, Lycium barbarum, Phyllanthus emblica, Punica granatum and Vitis spp.
Furthermore, the above Type-2 Diabetes disease risk reducing dietary supplement includes: one or more components of: Aronia melanocarpa, Citrus limonum, Daucus carota, Hibiscus spp., Malus domestica, Ribes nigrum, Sambucus nigra and Vaccinium spp.
Furthermore, the above Type-2 Diabetes disease risk reducing dietary supplement includes: one or more components of: ebselen (or glutathione or N-acetyl-L-cysteine) and nano encapsulated superoxide dismutase (SOD).
Furthermore, the above Type-2 Diabetes disease risk reducing dietary supplement includes: one or more components of: pterostilbene, quercetin, resveratrol and sulforaphane.
Furthermore, the above Type-2 Diabetes disease risk reducing dietary supplement includes: one or more components of: a mineral and a vitamin.
[D] A dietary super antioxidant dietary supplement includes: any three components of a) Actinidia chinenesis, Ananas comosus, Cocos nucifera, Garcinia mangostana, Litchi chinensis and Vitis spp. b) components of: Aronia melanocarpa, Citrus limonum, Daucus carota, Hibiscus spp., Malus domestica, Ribes nigrum, Sambucus nigra and Vaccinium spp. c) coenzyme Q10.
Furthermore, the above dietary super antioxidant dietary supplement includes: one or more components of: ebselen (or glutathione or N-acetyl-L-cysteine) and nano encapsulated superoxide dismutase (SOD).
Furthermore, the above dietary super antioxidant dietary supplement includes: one or more components of: citicoline, D-Ribose, L-analyl-L-glutamine and theanine.
Furthermore, the above dietary super antioxidant dietary supplement includes: one or more components of: plant sterol, pterostilbene, quercetin and resveratrol.
Furthermore, the above dietary super antioxidant dietary supplement includes: one or more components of: a mineral and a vitamin.
[E] A dietary sweetener includes: erythritol and Stevia rebaudiana.
The above sweetener further includes: one or more components of: Capparis masaikai.
The above sweetener further includes: one or more components of: Curculigo latifolia.
The above sweetener further includes: one or more components of: Dioscoreophyllum cumminsii.
The above sweetener further includes: one or more components of: Momordica/Siraitia grosvenorii.
The above sweetener further includes: one or more components of: Pentadiplandra brazzeana.
The above sweetener further includes: one or more components of: Synsepalum dulcificum.
The above sweetener further includes: one or more components of: Thaumatococcus daniellii.
[F] A nano assembly (as in
[G] A nano assembly (as in
[H] A nano assembly (as in
[I] A nano assembly (as in
[J] A nano assembly (as in
[K] A long-term micro patch includes: a) a nano crystal for nano assembling of bioactive compounds and/or bioactive molecules, b) a MEMS reservoir for storing the nano crystal with the bioactive compound and/or the bioactive molecule, c) a thin-film for attaching with the MEMS reservoir and d) a bioactive compound and/or a bioactive molecule.
[L] A short-term micro patch includes: a) a nano crystal for nano assembling of bioactive compounds and/or bioactive molecules, b) a thin-film for attaching with the nano crystals and c) a bioactive compound and/or a bioactive molecule.
[M] A passive method of delivering the bioactive compounds and/or bioactive molecules, which utilizes a MEMS reservoir with monolithically integrated microneedles.
[N] An active method of delivering the bioactive compounds and/or bioactive molecules, which utilizes a MEMS reservoir with monolithically integrated microneedles, where the MEMS reservoir further includes: an electrically powered micropump.
[O] A bioelectronics subsystem includes: a) a MEMS based blood drawing module, b) a photonic-crystal based optical diagnostic module, c) a graphene based electrical diagnostics module and d) a MEMS based active delivery module.
Furthermore the above bioelectronics subsystem includes: a) a needle for penetrating into skin (e.g., the skin of a human body) for collecting blood, b) a fluidic channel for guiding blood onto a biomolecular interface layer, c) the biomolecular interface layer for interacting with a biomarker and a receptor, d) the receptor for binding with the biomarker, e) a photonic crystal structure for a change in optical characteristics due to an interaction of the biomarker with the receptor on the biomolecular layer, 1) a laser for incident light onto the photonic crystal structure, g) a device for measuring the change in optical characteristics, h) a graphene field-effect transistor (FET) for measuring a change in electrical characteristics due to an interaction of the biomarker with the receptor on the biomolecular layer, i) a bioactive compound and/or a bioactive molecule, j) a MEMS reservoir for storing the bioactive compound and/or the bioactive molecule and k) a pump for propagating the bioactive compound an/or the bioactive molecule through the skin.
Furthermore the above bioelectronics subsystem includes: one or more components of: an electrical charge, a fluorophore, an immune surveillance evading functional molecule, a nano crystal and a targeting ligand molecule.
Furthermore the above bioelectronics subsystem includes: one or more components of: an optical beam diffuser, an optical beam splitter, a voltage controlled membrane and a v-groove.
Furthermore the above bioelectronics subsystem includes: one or more components of: a microprocessor component, a memory/data storage component, a wireless communication component, an electrical powering component and an algorithm.
Furthermore the above bioelectronics subsystem utilizes: an intelligent expert diagnostic algorithm of diseases at a remote/cloud server.
[P] A retinal contact lens includes: a micro patch (as mentioned in K or L) for delivering the bioactive compounds and/or bioactive molecules.
[Q] The above retinal contact lens further includes: a biosensor component and a biosensor read-out component.
[R] The above retinal contact lens further includes: an optical component (an array of microlens and/or quantum dot displays).
[S] The above retinal contact lens further includes: a solar cell component.
[T] The retinal contact lens in [R] has many types of light-absorbing dye molecules (e.g., porphyrins and phthalocyanines) embedded in nano crystals.
[U] The above retinal contact lens further includes: a battery (thin-film/printed) component.
[V] The above retinal contact lens further includes: a radio component.
[W] The above retinal contact lens further includes: an antenna component.
The above disclosed descriptions are only the most preferred embodiments of the present invention. However it is not intended to be limiting. Numerous variations and/or modifications are possible within the scope of the present invention.
The present application is a continuation-in-part (CIP) of and claims priority to U.S. Non-provisional patent application Ser. No. 12/573,012, entitled, “NUTRITIONAL SUPPLEMENT FOR THE PREVENTION OF CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE, DIABETES AND REGULATION AND REDUCTION OF BLOOD SUGAR AND INSULIN RESISTANCE”, filed on Oct. 2, 2009.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12573012 | Oct 2009 | US |
| Child | 13135832 | US |
